MdxHealth (TM) : MDxHealth Announces Publication of Health Economic Analysis Demonstrating Cost-Savings of ConfirmMDx for

 MdxHealth (TM) : MDxHealth Announces Publication of Health Economic Analysis
         Demonstrating Cost-Savings of ConfirmMDx for Prostate Cancer

Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated
Prostate Biopsies and Reduce Healthcare Spending

IRVINE, CA,  and LIEGE,  BELGIUM -  February  14, 2013  - MDxHealth  SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic  tests to  support cancer  diagnosis and  treatment, 
today announced the publication of results from a health economic study in the
Journal of  American  Health  &  Drug Benefits.  The  budget  impact  analysis 
demonstrated  achievable  cost  savings  of  MDxHealth's  ConfirmMDx(TM)   for 
Prostate Cancer test,  which is  used by urologists  to identify  men who  may 
avoid  unnecessary  repeat   prostate  biopsies,   thereby  reducing   overall 
healthcare spending.

The analysis projected the benefits, costs, and cost savings of the ConfirmMDx
for  Prostate  Cancer  test  based  on  empirical  evidence  of  its  clinical 
effectiveness compared to a standard of care reference scenario not using  the 
assay. The goal  was to  quantify the impact  on costs  by avoiding  medically 
unnecessary repeat prostate biopsy procedures for  a managed care plan of  one 
million members that reimburses for the ConfirmMDx for Prostate Cancer test. A
budget impact model was built to  test the hypothesis that the ConfirmMDx  for 
Prostate Cancer test can produce cost savings to payers as well as benefits to
urologists and patients by  providing actionable guidance  to treat with  more 
appropriate and less costly care.

The analysis demonstrated  that a  commercial health plan  would realize  cost 
savings within the first year of establishing coverage for the ConfirmMDx  for 
Prostate Cancer test. The upfront cost will be recovered based on the savings
associated with avoided biopsy procedures and associated complications. Given
these assumptions and the costs associated with the current standard of  care, 
the inclusion of  the test into  the management of  men screened for  prostate 
cancer resulted in a net cost savings of $588.00 per patient or budget impact
of  in a managed care plan of one million members.

"Even with conservative assumptions,  our budget impact analysis  demonstrates 
that the ConfirmMDx for Prostate Cancer test can provide economic returns that
may generate net cost savings to health plans by reducing unnecessary prostate
biopsies, thus improving clinical management and patient outcomes," said  lead 
author Wade Aubry,  M.D., Senior  Medical Director for  Quorum Consulting  and 
Associate Clinical Professor of Medicine at the University of California, San
Francisco. "ConfirmMDx  demonstrates the  exciting potential  of  personalized 
medicine. In  today's cost-conscious  healthcare environment,  well-validated 
molecular tests hold the promise to address not only unmet clinical needs, but
also provide health economic benefits."

About Prostate Cancer
Prostate cancer is the most frequent cancer in men worldwide, with one out  of 
six men being  diagnosed with  prostate cancer in  a lifetime.  In the  United 
States approximately  19 million  men are  screened with  the PSA  test on  an 
annual basis, leading  to more than  1.3 million biopsy  procedures and  about 
240,890 newly diagnosed cases.

About ConfirmMDx for Prostate Cancer
Over 650,000 American men receive a negative prostate biopsy result each year;
though approximately 25% of these men may still harbor occult prostate cancer.
This  well-documented  risk  of  undetected  cancer,  often  with   clinically 
significant Gleason scores, leads to a high rate of repeat biopsies with  over 
40% of men receiving at least one repeat biopsy, and many receiving a 3^rd and
4^th biopsy. Today's gold standard diagnostic approach is the prostate  biopsy 
procedure, collecting 10-12 needle core biopsy samples, however, this sampling
represents less than 1%  of the volume of  a man's prostate gland.  ConfirmMDx 
for Prostate  Cancer is  an epigenetic  assay to  help urologists  distinguish 
patients who have a true-negative biopsy from those at risk for occult cancer.
The test is  able to detect  an epigenetic field  effect or "halo"  associated 
with the cancerization process  at the DNA level  in cells adjacent to  cancer 
foci. This molecular  "halo" around  a cancer  lesion can  be present  despite 
having a normal  appearance under  the microscope. The  test helps  urologists 
rule out prostate cancer-free men from undergoing unnecessary repeat  biopsies 
and, helps rule  in high  risk patients who  may require  repeat biopsies  and 
potential treatment.

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients.  The  company's  first commercial  product,  the  ConfirmMDx  for 
Prostate Cancer test, has been shown  to help distinguish patients who have  a 
true-negative biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer diagnosis and
treatment information. The  company has  a proprietary platform  and a  strong 
epigenetic product pipeline focused on  the development of products for  brain 
and lung cancers. The company is  based in Irvine, California with a  European 
headquarters in Liege, Belgium. For  more information visit MDxHealth  website 
at www.mdxhealth.com.

Contacts 
Dr Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com

Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075
msinclair@halsin.com

Seth Lewis
The Trout Group
US: +1 646 378 2952
---
slewis@troutgroup.com

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law  or regulation.  This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service
marks are the property of their respective owners.

HEALTH ECONOMIC ENG

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1677896